STAT42%
Sales from controversial U.S. drug discount program rose to $100 billion last year 30%
By Ed Silverman61%
7/14/2026, 7:57:23 PM
BS Summary: This article contains 10 faulty reasoning types, including Status Quo Bias, Optimism Bias, and Middle Ground, with Framing Effect as the most egregious example at 33.3% saturation with 50 hits. Analysis detected 346 faulty-reasoning hits from 150 analyzed words, generating a BS Score of 40.3% and a BS Rank of 30% (14,410 of 20,518 articles). This article is better (less manipulative) than 70.20% of the article peer group.
Prescription medicines purchased in the U.S. under a controversial government discount program amounted to $100 billion in 2025, a 22.8% increase from the previous year, according to the Health Resources and Services Administration, which oversees the program.
Expensive medicines represented an increasing proportion of spending in the 340B Drug Discount Program, accounting for $61.9 billion, or nearly 62% of all prescription drugs purchased through the program.
Nearly $8.9 billion was spent on Merck’s Keytruda immunotherapy treatment, followed by more than $4.47 billion on Biktarvy, an HIV medicine sold by Gilead Sciences.
The data mark a steady rise in sales under the 340B program, which requires drugmakers to offer discounts that are typically estimated to be 25% to 50% — but could be higher — off all outpatient drugs to hospitals and clinics that primarily serve lower-income patients.
Speakers
1speaker25%attributed speech113writer words
Voice mapSelect a segment to jump to its words
Selected voice
100%flagged-word coverageHealth Resources and Services Administration
37 attributed words100% of attributed speech100% writer coverage
Attribution is sentence-level. Pattern percentages are calculated only from words assigned to that voice.
Loading…
Loading…
Loading…
Loading…
Analysis
Hover over highlighted words in the article to view the associated bias or fallacy analysis.